Monoclonal antibodies (mAbs) Biosimilars Market Report

Global and Region Monoclonal antibodies (mAbs) Biosimilars Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：146
  • REPORT CODE：GMM992022
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.

    The report details the trend, potential and market size of Monoclonal antibodies (mAbs) Biosimilars market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Monoclonal antibodies (mAbs) Biosimilarsmarket, defines the market attractiveness level of Monoclonal antibodies (mAbs) Biosimilars market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Monoclonal antibodies (mAbs) Biosimilars industry, describes the types of Monoclonal antibodies (mAbs) Biosimilars market, the applications of major players and the market size, and deeply analyzes the current situation of the global Monoclonal antibodies (mAbs) Biosimilars market and the development prospects and opportunities of Monoclonal antibodies (mAbs) Biosimilars industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Monoclonal antibodies (mAbs) Biosimilars market in Chapter 13.

    By Player:

    • Others

    • Celltrion

    • Accord Healthcare

    • 3SBio

    • AET Biotech

    • Dr Reddy's Laboratories

    • Hospira

    • Biocon

    • Allergan

    • Amega Biotech

    By Type:

    • Erythropoietin (EPO)

    • Human Growth Hormone (HGH)

    • Granulocyte- Colony Stimulating Factor (G-CSF)

    • Monoclonal Antibody (mAb)

    • Insulin

    • Interferon (IFN)

    • Amega Biotech

    By End-User:

    • Anti-Cancer

    • Anti-Inflammatory/Autoimmune

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Monoclonal antibodies (mAbs) Biosimilars Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Monoclonal antibodies (mAbs) Biosimilars Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Monoclonal antibodies (mAbs) Biosimilars Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Monoclonal antibodies (mAbs) Biosimilars Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Monoclonal antibodies (mAbs) Biosimilars Market Analysis and Outlook to 2022

    • 7.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    • 7.2 United States Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    • 7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    • 7.4 China Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    • 7.5 Japan Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    • 7.6 India Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    • 7.7 South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)

    8 Region and Country-wise Monoclonal antibodies (mAbs) Biosimilars Market Analysis and Outlook to 2028

    • 8.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    • 8.2 United States Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    • 8.3 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    • 8.4 China Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    • 8.5 Japan Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    • 8.6 India Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    • 8.7 South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)

    9 Global Monoclonal antibodies (mAbs) Biosimilars Market Outlook by Types and Applications to 2022

    • 9.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Erythropoietin (EPO) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Human Growth Hormone (HGH) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Monoclonal Antibody (mAb) Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Insulin Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Interferon (IFN) Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Amega Biotech Consumption and Growth Rate (2017-2022)

    • 9.2 Global Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Anti-Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Anti-Inflammatory/Autoimmune Consumption and Growth Rate (2017-2022)

    10 Global Monoclonal antibodies (mAbs) Biosimilars Market Outlook by Types and Applications to 2028

    • 10.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Erythropoietin (EPO) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Human Growth Hormone (HGH) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Monoclonal Antibody (mAb) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Insulin Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Interferon (IFN) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.7 Global Amega Biotech Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Anti-Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Anti-Inflammatory/Autoimmune Consumption Forecast and Growth Rate (2022-2028)

    11 Global Monoclonal antibodies (mAbs) Biosimilars Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Monoclonal antibodies (mAbs) Biosimilars Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Monoclonal antibodies (mAbs) Biosimilars Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Monoclonal antibodies (mAbs) Biosimilars Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Monoclonal antibodies (mAbs) Biosimilars Market Competitive Analysis

    • 14.1 Others

      • 14.1.1 Others Company Details

      • 14.1.2 Others Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Others Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.2 Celltrion

      • 14.2.1 Celltrion Company Details

      • 14.2.2 Celltrion Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.3 Accord Healthcare

      • 14.3.1 Accord Healthcare Company Details

      • 14.3.2 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.4 3SBio

      • 14.4.1 3SBio Company Details

      • 14.4.2 3SBio Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.5 AET Biotech

      • 14.5.1 AET Biotech Company Details

      • 14.5.2 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.6 Dr Reddy's Laboratories

      • 14.6.1 Dr Reddy's Laboratories Company Details

      • 14.6.2 Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.7 Hospira

      • 14.7.1 Hospira Company Details

      • 14.7.2 Hospira Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.8 Biocon

      • 14.8.1 Biocon Company Details

      • 14.8.2 Biocon Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.9 Allergan

      • 14.9.1 Allergan Company Details

      • 14.9.2 Allergan Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • 14.10 Amega Biotech

      • 14.10.1 Amega Biotech Company Details

      • 14.10.2 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Monoclonal antibodies (mAbs) Biosimilars

    • Figure Monoclonal antibodies (mAbs) Biosimilars Picture

    • Table Global Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Monoclonal antibodies (mAbs) Biosimilars Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)

    • Figure United States Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Japan Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure India Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure United States Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Erythropoietin (EPO) Consumption and Growth Rate (2017-2022)

    • Figure Global Human Growth Hormone (HGH) Consumption and Growth Rate (2017-2022)

    • Figure Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal Antibody (mAb) Consumption and Growth Rate (2017-2022)

    • Figure Global Insulin Consumption and Growth Rate (2017-2022)

    • Figure Global Interferon (IFN) Consumption and Growth Rate (2017-2022)

    • Figure Global Amega Biotech Consumption and Growth Rate (2017-2022)

    • Figure Global Anti-Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Anti-Inflammatory/Autoimmune Consumption and Growth Rate (2017-2022)

    • Figure Global Erythropoietin (EPO) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Human Growth Hormone (HGH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoclonal Antibody (mAb) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Interferon (IFN) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Amega Biotech Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anti-Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anti-Inflammatory/Autoimmune Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Monoclonal antibodies (mAbs) Biosimilars Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Monoclonal antibodies (mAbs) Biosimilars Export by Region (Top 5 Countries) (2017-2028)

    • Table Others (Foundation Year, Company Profile and etc.)

    • Table Others Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Others Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Celltrion (Foundation Year, Company Profile and etc.)

    • Table Celltrion Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Accord Healthcare (Foundation Year, Company Profile and etc.)

    • Table Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table 3SBio (Foundation Year, Company Profile and etc.)

    • Table 3SBio Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table AET Biotech (Foundation Year, Company Profile and etc.)

    • Table AET Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Dr Reddy's Laboratories (Foundation Year, Company Profile and etc.)

    • Table Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Hospira (Foundation Year, Company Profile and etc.)

    • Table Hospira Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Biocon (Foundation Year, Company Profile and etc.)

    • Table Biocon Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Allergan (Foundation Year, Company Profile and etc.)

    • Table Allergan Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Service

    • Table Amega Biotech (Foundation Year, Company Profile and etc.)

    • Table Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US